David Dadiomov

Prevalence and distribution of high‐risk prescription opioid use in the United States, 2011–2016

D. Qato, R. Trotzky-Sirr, Carter D McCormick, 2021, Pharmacoepidemiology and drug safety.

Providing Low-barrier Addiction Treatment Via a Telemedicine Consultation Service During the COVID-19 Pandemic in Los Angeles, County: An Assessment 1 Year Later.

Gina Rossetti, R. Trotzky-Sirr, K. Ragins, 2022, Journal of addiction medicine.

Safety of Repeated Administration of Parenteral Ketamine for Depression

D. Feifel, David Dadiomov, K. C. Lee, 2020, Pharmaceuticals.

The effects of ketamine on suicidality across various formulations and study settings

Kelly C. Lee, David Dadiomov, 2019, The mental health clinician.

Laboratory Testing for Substance Use Disorders

David Dadiomov, 2020, Absolute Addiction Psychiatry Review.

Changes in the availability of medications for opioid use disorder in prisons and jails in the United States during the COVID-19 pandemic

D. Qato, R. Trotzky-Sirr, David Dadiomov, 2022, Drug and Alcohol Dependence.

Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic.

Tran H. Tran, Alyssa M. Peckham, Lucas G. Hill, 2021, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic

M. Bolshakova, R. Trotzky-Sirr, David Dadiomov, 2022, Harm Reduction Journal.

Dissociating the Clinical Role and Economic Value of Intranasal Esketamine

David Dadiomov, 2020, Journal of managed care & specialty pharmacy.